keyword
MENU ▼
Read by QxMD icon Read
search

Breast cancer her2+ recurrence

keyword
https://www.readbyqxmd.com/read/28090417/pattern-of-local-recurrence-and-distant-metastasis-in-breast-cancer-by-molecular-subtype
#1
Xingrao Wu, Ayesha Baig, Goulnar Kasymjanova, Kamran Kafi, Christina Holcroft, Hind Mekouar, Annie Carbonneau, Boris Bahoric, Khalil Sultanem, Thierry Muanza
BACKGROUND AND PURPOSE:  No longer considered a single disease entity, breast cancer is being classified into several distinct molecular subtypes based on gene expression profiling. These subtypes appear to carry prognostic implications and have the potential to be incorporated into treatment decisions. In this study, we evaluated patterns of local recurrence (LR), distant metastasis (DM), and association of survival with molecular subtype in breast cancer patients in the post-adjuvant radiotherapy setting...
December 9, 2016: Curēus
https://www.readbyqxmd.com/read/28064383/algorithms-for-prediction-of-the-oncotype-dx-recurrence-score-using-clinicopathologic-data-a-review-and-comparison-using-an-independent-dataset
#2
REVIEW
Michael R Harowicz, Timothy J Robinson, Michaela A Dinan, Ashirbani Saha, Jeffrey R Marks, P Kelly Marcom, Maciej A Mazurowski
PURPOSE: Given the potential savings in cost and resource utilization, several algorithms have been proposed to predict Oncotype DX recurrence score (ODX RS) using commonly acquired histopathologic variables. Although it is promising, additional independent validation of these surrogate markers is needed prior to guide the patient management. METHODS: In this retrospective study, we analyzed 305 patients with invasive breast cancer at our institution who had ODX RS available...
January 7, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28063695/ipsilateral-axillary-recurrence-after-breast-conservative-surgery-the-protective-effect-of-whole-breast-radiotherapy
#3
Oreste Gentilini, Edoardo Botteri, Maria Cristina Leonardi, Nicole Rotmensz, Jose Vila, Nickolas Peradze, Maria Virginia Thomazini, Barbara Alicja Jereczek, Viviana Galimberti, Alberto Luini, Paolo Veronesi, Roberto Orecchia
BACKGROUND AND PURPOSE: Whole breast radiotherapy (WBRT) is one of the possible reasons for the low rate of axillary recurrence after breast-conserving surgery (BCS). PATIENTS AND METHODS: We retrospectively collected data from 4,129 consecutive patients with breast cancer ⩽2cm and negative sentinel lymph node who underwent BCS between 1997 and 2007. We compared the risk of axillary lymph node recurrence between patients treated by WBRT (n=2939) and patients who received partial breast irradiation (PBI; n=1,190) performed by a single dose of electron intraoperative radiotherapy...
January 4, 2017: Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology
https://www.readbyqxmd.com/read/28061634/personalized-medicine-approach-for-an-exceptional-response-to-multiple-recurrent-and-metastatic-her2-positive-oropharyngeal-squamous-cell-carcinoma
#4
Nolan B Seim, Stephen Y Kang, Milan Bhandari, Riley G Jones, Theodoros N Teknos
INTRODUCTION: Advanced stage squamous cell carcinoma of the head and neck carries an overall poor prognosis, and survivorship gains have remained relatively stagnant compared to other malignancies due to its complex tumor biology and lack of proven effective targeting agents. METHODS: We present a case of an exceptional responder to molecular-targeted therapy for metastatic oropharyngeal squamous cell carcinoma using a chemotherapeutic agent FDA approved for breast cancer and targeting the HER2/Neu receptor in order to discuss the larger clinical implications...
January 1, 2017: Annals of Otology, Rhinology, and Laryngology
https://www.readbyqxmd.com/read/28058615/complete-remission-in-metastatic-breast-cancer-expecting-the-unexpected-results-of-a-cross-sectional-study
#5
Giulia Galli, Anna Tessari, Luca Porcu, Giacomo Bregni, Biagio Paolini, Maria Luisa Carcangiu, Massimiliano Gennaro, Maria Carmen De Santis, Laura Lozza, Filippo de Braud, Serena Di Cosimo
BACKGROUND: Complete response (CR) in metastatic breast cancer (MBC) is rare. This study aims at analyzing the characteristics and outcome of MBC patients achieving CR. METHODS: We performed a cross-sectional analysis of clinical data from a consecutive series of MBC patients admitted at the Division of Medical Oncology of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, achieving CR following treatment for systemic disease and with at least 2 years of follow-up...
January 5, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28052766/biopsy-of-breast-cancer-metastases-patient-characteristics-and-survival
#6
Shlomit Strulov Shachar, Tanya Mashiach, Georgeta Fried, Karen Drumea, Noa Shafran, Hyman B Muss, Gil Bar-Sela
BACKGROUND: Discordance in hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status between primary tumors and metastatic sites for breast cancer is well established. However, it is uncertain which patient-related factors lead to biopsy when metastases are suspected and whether having a biopsy impacts survival. METHODS: The medical charts of metastatic breast cancer (MBC) patients diagnosed January 2000-August 2014 were retrospectively reviewed...
January 4, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28045912/claudin-low-breast-cancer-clinical-pathological-characteristics
#7
Kay Dias, Anna Dvorkin-Gheva, Robin M Hallett, Ying Wu, John Hassell, Gregory R Pond, Mark Levine, Tim Whelan, Anita L Bane
Claudin-low breast cancer is a molecular type of breast cancer originally identified by gene expression profiling and reportedly associated with poor survival. Claudin-low tumors have been recognised to preferentially display a triple-negative phenotype, however only a minority of triple-negative breast cancers are claudin-low. We sought to identify an immunohistochemical profile for claudin-low tumors that could facilitate their identification in formalin fixed paraffin embedded tumor material. First, an in silico collection of ~1600 human breast cancer expression profiles was assembled and all claudin-low tumors identified...
2017: PloS One
https://www.readbyqxmd.com/read/28039703/receptor-discordance-rate-and-its-effects-on-survival-in-primary-and-recurrent-breast-cancer-patients
#8
Serkan Ilgun, Dauren Sarsenov, Zeynep Erdogan, Cetin Ordu, Filiz Celebi, Kezban Nur Pilanci, Alper Ozturk, Derya Selamoglu, Gul Alco, Fatma Aktepe, Yesim Eralp, Sitki Tuzlali, Vahit Ozmen
PURPOSE: The receptor status of breast cancer plays a critical role in clinical practice. During the metastatic process, a change in the biological characteristics of the tumor can be seen. This study aimed to investigate the hormone receptor and HER2 status changes between primary and recurrent breast cancers and their effect on survival. METHODS: Eighty-six breast cancer patients with biopsy- proven local recurrences or distant metastases during the follow-up period were included in the study...
November 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28028262/-maintenance-of-long-term-stable-disease-sd-in-metastatic-breast-cancer-with-eribulin-a-case-report-of-long-term-sd-in-japan
#9
Toshikatsu Nitta, Kousei Kimura, Tomo Tominaga, Kensuke Fujii, Nayuko Sato, Ayana Ikari, Kazuhiro Miyoshi, Satoru Tanaka, Takashi Ishibashi, Mitsuhiko Iwamoto
This case report discusses a 48-year-old woman with metastatic breast cancer: T4c(10.5 cm)N2bM1,(OSS, LYM), stage IV, estrogen receptor(ER)(+), progesterone receptor(PgR)(+), human epidermal growth factor receptor-2(HER2) (-), and Ki-67 17.2%. Administration of eribulin was initiated after treatment with anthracycline and taxane. Thereafter, 28 courses of eribulin maintained a SD state for over a year and improved the quality of life(QOL). Eribulin is effective for both prolonging life and improving QOL, which are the main goals in the treatment of metastatic or recurrent cancer...
December 2016: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28027219/cancer-risk-after-fat-transfer-a-multicenter-case-cohort-study
#10
Terence M Myckatyn, I Janelle Wagner, Babak J Mehrara, Melissa A Crosby, Julie E Park, Bahjat F Qaqish, Dominic T Moore, Evan L Busch, Amanda K Silva, Surinder Kaur, David W Ollila, Clara N Lee
BACKGROUND: Fat transfer is an increasingly popular method for refining postmastectomy breast reconstructions. However, concern persists that fat transfer may promote disease recurrence. Adipocytes are derived from adipose-derived stem cells and express adipocytokines that can facilitate active breast cancer cells in laboratory models. The authors sought to evaluate the association between fat transfer to the reconstructed breast and cancer recurrence in patients diagnosed with local or regional invasive breast cancers...
January 2017: Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/28012085/the-influence-of-21-gene-recurrence-score-assay-on-chemotherapy-use-in-a-population-based-sample-of-breast-cancer-patients
#11
Yun Li, Allison W Kurian, Irina Bondarenko, Jeremy M G Taylor, Reshma Jagsi, Kevin C Ward, Ann S Hamilton, Steven J Katz, Timothy P Hofer
PURPOSE: To quantify the influence of RS assay on changing chemotherapy plans in a general practice setting using causal inference methods. METHODS: We surveyed 3880 newly diagnosed breast cancer patients in Los Angeles and Georgia in 2013-14. We used inverse propensity weighting and multiple imputations to derive complete information for each patient about treatment status with and without testing. RESULTS: A half of the 1545 women eligible for testing (ER+ or PR+, HER2-, and stage I-II) received RS...
February 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28004220/recurrence-risk-perception-and-quality-of-life-following-treatment-of-breast-cancer
#12
Sarah T Hawley, Nancy K Janz, Kent A Griffith, Reshma Jagsi, Christopher R Friese, Allison W Kurian, Ann S Hamilton, Kevin C Ward, Monica Morrow, Lauren P Wallner, Steven J Katz
PURPOSE: Little is known about different ways of assessing risk of distant recurrence following cancer treatment (e.g., numeric or descriptive). We sought to evaluate the association between overestimation of risk of distant recurrence of breast cancer and key patient-reported outcomes, including quality of life and worry. METHODS: We surveyed a weighted random sample of newly diagnosed patients with early-stage breast cancer identified through SEER registries of Los Angeles County & Georgia (2013-14) ~2 months after surgery (N = 2578, RR = 71%)...
February 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/27986267/-evaluation-of-the-immune-infiltrate-in-breast-cancer
#13
REVIEW
Nina Radosevic-Robin, Marie Béguinot, Frédérique Penault-Llorca
Tumour-infiltrating lymphocytes (TIL) are major components of the immune/"inflammatory" infiltrate found in tumour microenvironment. They reflect the intensity and the quality of the immune reaction to cancer. In breast cancer, TIL density and phenotypic profile have been demonstrated to be predictive of response to neoadjuvant treatment and of patient outcome. TIL density, currently the best-developed TIL-related biomarker, is defined as the percentage of tumour stroma surface occupied by TIL. The baseline TIL density of 50% and higher is associated with particularly high rates of pathological complete response to neoadjuvant therapy in triple negative and HER2+ breast cancer, as well as with significantly better recurrence-free and overall survival...
December 13, 2016: Bulletin du Cancer
https://www.readbyqxmd.com/read/27983617/molecular-mechanisms-and-translational-therapies-for-human-epidermal-receptor-2-positive-breast-cancer
#14
REVIEW
Quanxia Lv, Ziyuan Meng, Yuanyuan Yu, Feng Jiang, Daogang Guan, Chao Liang, Junwei Zhou, Aiping Lu, Ge Zhang
Breast cancer is the second leading cause of cancer death among women. Human epidermal receptor 2 (HER2) positive breast cancer (HER2+ BC) is the most aggressive subtype of breast cancer, with poor prognosis and a high rate of recurrence. About one third of breast cancer is HER2+ BC with significantly high expression level of HER2 protein compared to other subtypes. Therefore, HER2 is an important biomarker and an ideal target for developing therapeutic strategies for the treatment HER2+ BC. In this review, HER2 structure and physiological and pathological roles in HER2+ BC are discussed...
December 14, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27972496/estimated-costs-of-locoregional-and-metastatic-recurrences-in-patients-with-her2-breast-cancer-in-spain
#15
J Albanell, E Ciruelos, J De la Haba, M Martín, B Muñoz-Molina, M De Salas-Cansado, R Colomer
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27964843/tumour-infiltrating-lymphocytes-in-advanced-her2-positive-breast-cancer-treated-with-pertuzumab-or-placebo-in-addition-to-trastuzumab-and-docetaxel-a-retrospective-analysis-of-the-cleopatra-study
#16
Stephen J Luen, Roberto Salgado, Stephen Fox, Peter Savas, Jennifer Eng-Wong, Emma Clark, Astrid Kiermaier, Sandra M Swain, Jose Baselga, Stefan Michiels, Sherene Loi
BACKGROUND: High quantities of tumour-infiltrating lymphocytes (TILs) in primary HER2-positive breast cancer are associated with improved prognosis and response to therapy. We aimed to investigate the prognostic role of host antitumour immunity as represented by baseline quantities of TILs in patients with advanced HER2-positive breast cancer treated with either pertuzumab or placebo in addition to trastuzumab and docetaxel. METHODS: CLEOPATRA was a randomised phase 3 study comparing the addition of either pertuzumab or placebo to first-line therapy with trastuzumab and docetaxel for patients with locally recurrent, unresectable, or metastatic HER2-positive breast cancer...
January 2017: Lancet Oncology
https://www.readbyqxmd.com/read/27926948/intrinsic-subtype-switching-and-acquired-erbb2-her2-amplifications-and-mutations-in-breast-cancer-brain-metastases
#17
Nolan Priedigkeit, Ryan J Hartmaier, Yijing Chen, Damir Vareslija, Ahmed Basudan, Rebecca J Watters, Roby Thomas, Jose P Leone, Peter C Lucas, Rohit Bhargava, Ronald L Hamilton, Juliann Chmielecki, Shannon L Puhalla, Nancy E Davidson, Steffi Oesterreich, Adam M Brufsky, Leonie Young, Adrian V Lee
Importance: Patients with breast cancer (BrCa) brain metastases (BrM) have limited therapeutic options. A better understanding of molecular alterations acquired in BrM could identify clinically actionable metastatic dependencies. Objective: To determine whether there are intrinsic subtype differences between primary tumors and matched BrM and to uncover BrM-acquired alterations that are clinically actionable. Design, Setting, and Participants: In total, 20 cases of primary breast cancer tissue and resected BrM (10 estrogen receptor [ER]-negative and 10 ER-positive) from 2 academic institutions were included...
December 7, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27923043/clonal-evolutionary-analysis-during-her2-blockade-in-her2-positive-inflammatory-breast-cancer-a-phase-ii-open-label-clinical-trial-of-afatinib-vinorelbine
#18
Gerald Goh, Ramona Schmid, Kelly Guiver, Wichit Arpornwirat, Imjai Chitapanarux, Vinod Ganju, Seock-Ah Im, Sung-Bae Kim, Arunee Dechaphunkul, Jedzada Maneechavakajorn, Neil Spector, Thomas Yau, Mehdi Afrit, Slim Ben Ahmed, Stephen R Johnston, Neil Gibson, Martina Uttenreuther-Fischer, Javier Herrero, Charles Swanton
BACKGROUND: Inflammatory breast cancer (IBC) is a rare, aggressive form of breast cancer associated with HER2 amplification, with high risk of metastasis and an estimated median survival of 2.9 y. We performed an open-label, single-arm phase II clinical trial (ClinicalTrials.gov NCT01325428) to investigate the efficacy and safety of afatinib, an irreversible ErbB family inhibitor, alone and in combination with vinorelbine in patients with HER2-positive IBC. This trial included prospectively planned exome analysis before and after afatinib monotherapy...
December 2016: PLoS Medicine
https://www.readbyqxmd.com/read/27920688/complete-and-sustained-response-with-a-doublet-chemotherapy-protocol-in-an-81-year-old-patient-with-metastatic-breast-cancer
#19
Taynah Cascaes Puty, Gabriel S A Brito, Mariana S Dias, Henrique C Miranda, Juliana R Chaves, Heryvelton L Freitas, Luís E W Carvalho
Metastatic breast cancer (MBC) entails an overall 5-year survival of approximately 25%. The choice of therapy is influenced by expression of the HER2 gene and hormone receptors, by a disease-free interval, and by age. The use of paclitaxel combined with gemcitabine (doublet protocol) has shown efficacy as first-line treatment for MBC in either initial or maintenance therapy when compared to monotherapy with paclitaxel. There is evidence showing that the doublet protocol is a good alternative to maintenance therapy in women under 50 years old...
September 2016: Case Reports in Oncology
https://www.readbyqxmd.com/read/27919974/a-phase-ii-study-of-adjuvant-chemotherapy-of-tegafur-uracil-for-patients-with-breast-cancer-with-her2-negative-pathologic-residual-invasive-disease-after-neoadjuvant-chemotherapy
#20
Satoru Tanaka, Mitsuhiko Iwamoto, Kosei Kimura, Yuko Takahashi, Hiyoya Fujioka, Nayuko Sato, Risa Terasawa, Kanako Kawaguchi, Ayana Ikari, Tomo Tominaga, Saki Maezawa, Nodoka Umezaki, Junna Matsuda, Kazuhisa Uchiyama
BACKGROUND: There is no consensus on the need for adjuvant chemotherapy for patients with pathological residual invasive breast cancer (non-pCR) after neoadjuvant chemotherapy (NAC). We evaluated the tolerability and safety of tegafur-uracil (UFT) as adjuvant chemotherapy for patients with human epidermal growth factor receptor 2-negative breast cancer that resulted in non-pCR after NAC. PATIENTS AND METHODS: We treated patients with 270 mg/m(2) UFT per day for 2 years after definitive surgery and radiotherapy, if necessary...
2016: Anticancer Research
keyword
keyword
115348
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"